Resveratrol

( DrugBank: Resveratrol / KEGG DRUG: - )


5 diseases
IDDisease name (Link within this page)Number of trials
8Huntington disease1
18Spinocerebellar degeneration2
89Lymphangioleiomyomatosis1
IDDisease name (Link within this page)Number of trials
113Muscular dystrophy1
299Cystic fibrosis1

8. Huntington disease


Clinical trials : 276Drugs : 185 - (DrugBank : 58) / Drug target genes : 86 - Drug target pathways : 160 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

18. Spinocerebellar degeneration


Clinical trials : 83Drugs : 83 - (DrugBank : 31) / Drug target genes : 30 - Drug target pathways : 53 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

89. Lymphangioleiomyomatosis


Clinical trials : 44Drugs : 44 - (DrugBank : 20) / Drug target genes : 27 - Drug target pathways : 138 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

113. Muscular dystrophy


Clinical trials : 766Drugs : 477 - (DrugBank : 119) / Drug target genes : 80 - Drug target pathways : 178 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

299. Cystic fibrosis


Clinical trials : 1,826Drugs : 1,271 - (DrugBank : 246) / Drug target genes : 118 - Drug target pathways : 180 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries